Glaukos (GKOS) Competitors

Zimmer Biomet (NYSE:ZBH) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.

Does the MarketBeat Community believe in ZBH or GKOS?

Zimmer Biomet received 454 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 67.06% of users gave Zimmer Biomet an outperform vote while only 65.03% of users gave Glaukos an outperform vote.

Company	Underperform	Outperform
Zimmer Biomet	Outperform Votes 904 67.06%	Underperform Votes 444 32.94%
Glaukos	Outperform Votes 450 65.03%	Underperform Votes 242 34.97%

Do institutionals and insiders believe in ZBH or GKOS?

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by company insiders. Comparatively, 6.4% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has stronger earnings and valuation, ZBH or GKOS?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.68B	2.89	$903.70M	$4.45	25.01
Glaukos	$383.48M	15.89	-$134.66M	-$2.87	-37.53

Is ZBH or GKOS more profitable?

Zimmer Biomet has a net margin of 11.77% compared to Glaukos' net margin of -39.04%. Zimmer Biomet's return on equity of 12.99% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	11.77%	12.99%	7.58%
Glaukos	-39.04%	-16.53%	-10.61%

Which has more volatility & risk, ZBH or GKOS?

Zimmer Biomet has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

Do analysts recommend ZBH or GKOS?

Zimmer Biomet currently has a consensus price target of $124.15, suggesting a potential upside of 11.54%. Glaukos has a consensus price target of $163.25, suggesting a potential upside of 51.56%. Given Glaukos' stronger consensus rating and higher possible upside, analysts clearly believe Glaukos is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.32
Glaukos	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Does the media favor ZBH or GKOS?

In the previous week, Zimmer Biomet had 19 more articles in the media than Glaukos. MarketBeat recorded 26 mentions for Zimmer Biomet and 7 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 1.37 beat Glaukos' score of 1.33 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	22 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zimmer Biomet beats Glaukos on 12 of the 19 factors compared between the two stocks.